Antibody Drug Discovery Market is predicted to reach USD 13.37 billion at a CAGR of 8.90% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Antibody Drug Discovery Market”.

The antibody drug discovery market is attributed to register a CAGR of 8.90% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global antibody drug discovery market— Charles River Laboratories (US), Biocytogen Pharmaceuticals Co., Ltd (China), Sartorius AG (Germany), Genscript Biotech Corporation (US), Creative Biolabs (US), Twist Bioscience (US), Fairjourney Biologics SA (Portugal), ProteoGenix (US), Absolute Antibody (UK), and Sino Biological, Inc. (China), and others.

Market Highlights

The global antibody drug discovery market is estimated to register a CAGR of 8.90% during the forecast period and is projected to reach USD 13.37 billion by 2032.

The market is expanding due to factors such as the increasing prevalence of chronic diseases worldwide and rising demand for personalized medicine, which boost the global antibody drug discovery market's growth. Moreover, there are high chances of having chronic diseases such as cancer, autoimmune disorders, and infectious diseases among geriatric population which is boosting the demand of antibody drugs. Further, Type I is an autoimmune disease whose incidence is increasing across the world which is propelling the market growth. According to the International Diabetes Federation, approximately 8.75 million people were living with Type I diabetes in 2022. Thus, such an increase in the incidence of chronic diseases is creating a large and growing market for antibody-based therapies. Additionally, there is a growing focus on developing safer antibodies. For example, the drug Humira is a humanized antibody that is less likely to cause side effects than traditional murine antibodies. This type of safer antibody is expected to become more common in the future as the demand for drug safety increases.

However, the stringent regulatory policies and increasing demand for other drugs such as gene therapy and small-molecule drugs are limiting the market's growth. Moreover, advances in technologies such as phage display, high-throughput screening, and bioinformatics are making it easier to discover and develop new antibodies. This is leading to a more efficient and cost-effective drug discovery process and creating lucrative growth opportunities for the market during the forecast period.

Segment Analysis

The global antibody drug discovery market has been segmented based on type, application, technique, and end user.

On the basis of type, the market is segmented into monoclonal antibodies, polyclonal antibodies, bispecific antibodies, and intracellular antibodies. The monoclonal antibodies segment held the largest market share in 2022 due to their ability to treat various deadly diseases, including cancer and rare diseases such as uveal melanoma and cold agglutinin disease. As per the Antibody Society, numerous monoclonal antibody (mAb) therapeutics have been granted Orphan Drug designations. For instance, in January 2022, Immunocore Holdings plc. (UK) received approval for Tebentafusp from the US Food and Drug Administration, which treats a rare disease, namely uveal melanoma.

Based on technique, the global antibody drug discovery market has been segmented into hybridoma, phage display, and others, including transgenic mouse and single B cell techniques. The hybridoma segment dominated the market in 2022 and was the fastest-growing segment during the forecast period. This is due to its application, which can target specific molecules with great precision in research and antibody drug discovery. Moreover, hybridoma associated platform expansion is fuelling the segment growth. For instance, in Novermber 2022, Ablexis (US) and AlivaMab Discovery Services (US) expanded antibody drug discovery engineering capabilities. This platform is NGS-based hit-expansion capabilities that improve on the current sophisticated hybridoma-based methods used by AlivaMab Discovery Services and increase captured diversity.

The global antibody drug discovery market, based on application, has been segmented into oncology, cardiology, infectious diseases, autoimmune diseases, and others, including ophthalmology and neurology. The oncology segment held the largest market share in 2022 and is the fastest-growing segment during the forecast period, i.e., 2023 to 2032. Moreover, increasing infectious disease prevalence, such as malaria and acquired immunodeficiency diseases, is burgeoning the segment's growth. According to the World Health Organization, 39.0 million people were living with acquired immunodeficiency diseases in 2022, globally.

On the basis of end user, the global antibody drug discovery market has been segmented into pharmaceutical and biotechnology companies, contract research organizations, and academic & research institutes. Pharmaceutical and biotechnology companies accounted for the largest market share, and the contract research organizations segment was the fastest-growing segment during the forecast period owing to the increasing prevalence of cancer and rising adoption of technologically advanced platforms in regions such as North America and Europe.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of antibody drug discovery market Research Report

Regional Analysis

The global antibody drug discovery market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The Europe antibody drug discovery market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The antibody drug discovery market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World antibody drug discovery market comprises the Middle East, Africa, and Latin America.

The North America antibody drug discovery market held the largest market share in 2022 due to factors such as the increasing incidence of chronic diseases and the presence of major players such as Charles River Laboratories (US), Genscript Biotech Corporation (US), Creative Biolabs (US), and Twist Bioscience (US). Moreover, strategic alliances to accelerate antibody drug discovery are propelling segment growth. For instance, in June 2021, Eurofins Discovery (US) and ImmunoPrecise (Canada) collaborated to expand their antibody discovery platform. This collaboration provided access to Eurofins Discovery to use end-to-end antibody discovery capabilities using in vivo antibody discovery technologies.

Furthermore, the Europe antibody drug discovery market shows significant growth during the forecast period. This is due to the increasing prevalence of rare diseases and the active presence of giant players in the region. Furthermore, increasing funding and investment for drug discovery is creating opportunities for the region’s market. For instance, in February 2023, Icosagen AS (Estonia) entered into a financing agreement of USD 18.96 million with the European Investment Bank, which will boost biologic drug discovery and ultimately fuels antibody drug discovery growth in the region.  

Moreover, the Asia-Pacific antibody drug discovery market is representing the highest annual growth rate during the forecast period owing to increasing incidences of chronic diseases, which include infectious and autoimmune diseases. Moreover, market players are partnering in order to accelerate antibody drug discovery, which is propelling growth in the Asia-Pacific region. For instance, in December 2022, GenScript Biotech Corporation (US) partnered with Allozymes (Singapore), and this partnership boosted allozyme antibody production platform.

Additionally, the Middle East, Africa, and Latin America regions comprised the rest of the world. The region accounted for the lowest market share in the antibody drug discovery market due to the low adoption of technologically advanced antibody drug discovery platforms and a lack of government funding and investment. However, the increasing incidence of infectious diseases is driving the region’s growth. According to the World Health Organization, there has been an increase of 63% in disease spread from animals to humans in the last decade, i.e., 2012–2022.

Key Findings of the Study

• The global antibody drug discovery market is expected to reach USD 13.37 billion by 2032, at a CAGR of 8.90% during the forecast period.


• The Europe region shows significant growth during the forecast period due to the presence of major players and favorable government support for antibody drug discovery.


• Based on technique, the hybridoma segment held the largest market share in 2022, with an approximate market share of 45% to 55%.


• Charles River Laboratories (US), Biocytogen Pharmaceuticals Co., Ltd (China), Sartorius AG (Germany), Genscript Biotech Corporation (US), Creative Biolabs (US), Twist Bioscience (US), Fairjourney Biologics SA (Portugal), ProteoGenix (US), Absolute Antibody (UK), Sino Biological, Inc. (China), and others are the key market players.